[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dysplasia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dysplasia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,76,113],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100429093","a-study-comparing-the-effectiveness-of-endorotor-versus-radiofrequency-in-treating-barretts-esophagus-100429093",false,"NCT04867590","A Study Comparing the Effectiveness of EndoRotor Versus Radiofrequency in Treating Barrett's Esophagus","A Controlled, Randomised Multicenter Study Comparing the Effectiveness of EndoRotor (New Treatment Technique) Versus Radiofrequency (Reference Technique) in Treating Barrett's Esophagus Complicated by Dysplasia","ENDOBARRETT","Inclusion Criteria:\n\n* Adult patients presenting Barrett's esophagus of a size between 2 cm and 6 cm in the height of the longest tonguea with low to high grade dysplasia that is histologically proven or with a superficial non-invasive adenocarcinoma that has been resected a The total height of the BE is evaluated according to the Prague classification, with the height of the circumferential segment between 0 cm (non-circumferential segment) and 6 cm (segment shaped like a full sleeve for 6 cm), referred to as C0 to C6, and the height of the longest tongue between 2 cm and 6 cm (M2- M6).\n* Patients must have signed the consent form in order to participate in the study\n* Patients are pre-included (signature of consent) before the histological confirmation of dysplasiab and\u002For superficial non-invasive adenocarcinoma that allows the patient to be included in the study.\n\nExclusion Criteria:\n\n* Individuals over 85 years old\n* Women who are pregnant, breastfeeding or in labour\n* Individuals in detention through judicial or administrative decision\n* Individuals who are the subject of psychiatric treatment under duress\n* Individuals who are subjects of legal protection measures\n* Individuals who are in no state to give their consent\n* Individuals who do not understand French or do not know how to read\n* Individuals who are not part of a social security program or benefit from such a scheme\n* Those with active peptic and\u002For radiation-induced or complicated esophagitis at the time of treatment\n* Presence of a visible lesion that is suspected to be esophageal cancer confirmed by biopsies\n* Anterior resection of invasive adenocarcinoma using endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) with invasion of the lateral and\u002For deep margin, adenocarcinoma of poorly differentiated characteristics or sub-mucosal invasion \\> 500µm (pT1b)\n* All preliminary ablation treatments or dilation for esophageal stenosis\n* Significant esophageal stenosis: cannot be passed with a standard gastroscope\n* Presence of esophageal varices or portal hypertension\n* Anticoagulant treatment that cannot be stopped before the intervention (excluding 100 mg maximum per day of aspirin in single-drug treatment) or any haemostasis problems that cannot be corrected\n* Having a contraindication regarding anaesthesia\n* Patients incapable of taking proton pump inhibitors (PPIs) orally.","ALL","18 Years",{"count":20,"type":21},140,"ESTIMATED","INTERVENTIONAL",[24],"NA","Barrett Esophagus is a common pathology, with an estimated prevalence of 1.6% at risk of progression to precancerous mucosa (low to high grade dysplasia). The incidence of adenocarcinoma on BE is 0.5% per year. In the event of dysplasia or cancer in situ, it is currently recommended at international and particularly European level to eradicate BE. The treatment techniques used to date carry out thermal destruction of the BE, in particular by radiofrequency. Eradication of dysplasia is achieved in 81% to 100% and disappearance of BE in 73% to 87% of cases. It requires an average of 3 destruction sessions. RF does not allow histological analysis after destruction of BE, but the risk of progression to neoplasia is estimated at 7.8\u002F1000 persons per year. This risk could be due to the presence of glands buried in the esophageal mucosa. Indeed, these glands are not destroyed by thermal ablation methods, and remain invisible during endoscopic controls.\n\nA new treatment technique using the Endorotor® system allows mechanical resection of the entire mucosa in one session of treatment. In addition, the cost of these thermal destruction techniques currently limits their wider diffusion. It is therefore legitimate to propose a less expensive and probably more effective alternative technique.",[27,28],"Barrett Esophagus","Dysplasia","RECRUITING","2026-06-25",{"date":32,"type":33},"2026-06-30","ACTUAL",{"date":35,"type":33},"2022-03-25",{"date":37,"type":21},"2031-07-25",{"name":39,"class":40},"University Hospital, Angers","OTHER_GOV",17,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":59,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100544535","a-study-collecting-health-information-to-understand-and-prevent-gastric-cancer-100544535","NCT06370143","A Study Collecting Health Information to Understand and Prevent Gastric Cancer","Gastric Cancer Prevention: Understanding Precursor Lesions and Risk Factors for Progression to Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Able to read and understand English and Spanish\n* Meet criteria for one of three potentially eligible study populations:\n\n  * Individuals with gastric atrophy, gastric intestinal metaplasia, or dysplasia: Had a previous diagnosis of or have been diagnosed by the investigation team with gastric atrophy, gastric intestinal metaplasia, or dysplasia of the gastric mucosa on pathology review from an endoscopic biopsy. Individuals who have a prior history of early gastric cancer may be included, if they were treated endoscopically and have no evidence of disease. Individuals who have a prior history of a cancer other than upper gastrointestinal cancer may also be included, if they have no evidence of disease for at least 1 year prior to study enrollment and are not undergoing active treatment for any malignancy at any time throughout the study period\n  * Healthy controls (average risk): Individuals with no history of cancer or gastric precursor lesions undergoing a clinically indicated endoscopy at MSK for workup or dyspepsia or reflux\n  * Gastric cancer cases: Individuals with a known diagnosis of early gastric adenocarcinoma undergoing surgical resection at MSK\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old\n* Women who are pregnant (may be enrolled after delivery)\n* Individuals with a prior history of upper gastrointestinal surgery or a prior cancer who are undergoing active treatment for malignancy or have been diagnosed within 1 year prior to the study enrollment or with pancreatic cancer. (This does not include incidentally diagnosed primary gastric adenocarcinoma identified during study follow up. Individuals diagnosed with gastric carcinoid limited to the stomach will also be included, given their ongoing parallel risk for gastric adenocarcinoma.)\n* Have severe comorbidities with expected survival time \\\u003C2 years or which would prevent them from undergoing routine elective EGD (at the discretion of the patient's provider and the study team)\n* Individuals having Hereditary Diffuse Gastric Cancer Syndrome, mutations including CDH1 and CTNNA1, or more than one genetic mutation\n* Exclude high risk esophageal and duodenal lesions including:\n\n  * Duodenal Adenoma\n  * Dysplasia or cancer at the esophagus or gastroesophageal junction\n* Patients with an increased risk for biopsies during EGD, such as those with clotting disorders.",true,{"count":51,"type":21},3200,"OBSERVATIONAL","The purpose of this study is to create a registry of participants with precursor lesions for gastric cancer, including gastric atrophy, intestinal metaplasia, and dysplasia. Normal controls and individuals with gastric cancer for comparison of baseline characteristics will also be enrolled.",[55,56,28,57,58],"Gastric Atrophy","Gastric Intestinal Metaplasia","Gastric Adenocarcinoma","Gastric Cancer",[60,61,62,56,63,64,65],"Gastric cancer","gastric adenocarcinoma","gastric atrophy","dysplasia","Memorial Sloan Kettering Cancer Center","24-083","2026-01-28",{"date":68,"type":33},"2026-01-30",{"date":70,"type":33},"2024-04-11",{"date":72,"type":21},"2036-04-11",{"name":64,"class":74},"OTHER",7,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":49,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":85,"conditions":86,"keywords":91,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":112},"100601448","real-time-molecular-diagnosis-of-oral-precancer-100601448","NCT07110623","Real-time Molecular Diagnosis of Oral Precancer","LIP","Inclusion criteria for patients\n\n1. Adult aged 18 and older\n2. One of the following criteria must be met:\n\n   1. Has a medical condition for which biopsy of oral tissue has been indicated.\n   2. Is undergoing inspection for early oral cancer\n3. Willing and able to comply with all study procedures.\n\nExclusion criteria for patients\n\n1. Has a bleeding disorder, such as haemophilia, or has contraindication for having a biopsy.\n2. Severe co-morbid illness, such as end-stage renal failure (ESRF), congestive cardiac failure (CCF), severe osteoarthritis (OA) and rheumatoid arthritis (RA) requiring long term non-steroidal anti-inflammatory drug (NSAID) therapy and any other immunosuppression \u002F immuno-modulation therapy.\n3. Has other severe acute or chronic medical or psychiatric condition where use of the device may cause unnecessary stress\n4. Any condition that under judgment of the investigator would make the subject unsuitable as it may interfere with interpretation of study results\n5. Currently using any compound recognised as acting as a light sensitizer \u002F has a recognised condition associated with light sensitisation \u002F tissue sensitivity to light such as photodynamic therapy or lupus.\n6. Is pregnant or breastfeeding\n7. Has a laboratory abnormality in medical record that may interfere with the interpretation of study results\n\nInclusion criteria for healthy volunteers\n\n1. Adult aged 18 and older.\n2. Willing and able to comply with all study procedures.\n\nExclusion criteria for healthy volunteers\n\n1. Has a medical condition for which biopsy has been indicated or is undergoing inspection for early cancer.\n2. Severe co-morbid illness, such as end-stage renal failure (ESRF), congestive cardiac failure (CCF), severe osteoarthritis (OA) and rheumatoid arthritis (RA) requiring long term non-steroidal anti-inflammatory drug (NSAID) therapy and any other immunosuppression \u002F immuno-modulation therapy.\n3. Has other severe acute or chronic medical or psychiatric condition where use of the device may cause unnecessary stress\n4. Any condition that under judgment of the investigator would make the subject unsuitable as it may interfere with interpretation of study results\n5. Currently using any compound recognised as acting as a light sensitizer \u002F has a recognised condition associated with light sensitisation \u002F tissue sensitivity to light such as photodynamic therapy or lupus.\n6. Is pregnant or breastfeeding",{"count":84,"type":21},40,"The \"Real-time molecular diagnosis of oral precancer\" or the LIP study is testing a new device for the detection of cancer in the mouth.\n\nOral cancers are serious and devastating illnesses, especially if detected at a late stage. Currently, the detection of oral cancer relies on testing a biopsy, which involves cutting a small section of tissue from the mouth and sending it to the pathology laboratory for further testing. A doctor or dentist taking the biopsy must rely on their own eyesight and experience to spot areas of concern. It can therefore be difficult to detect the earliest stages of cancer. At times, cancer tissue is only detected because it has already developed, and this affects the success of the treatment.\n\nThe device tested in this study uses a laser beam to scan areas inside the mouth and a computer collects information about the scan. The goal of this project is to train the computer software in the device to recognize pre-cancer and cancer from normal scans. Patients who need to have a biopsy due to suspected pre-cancer or cancer in the mouth will be scanned with the device. Biopsy reports will be used to tell the software which scans were from pre-cancer or cancer or non-cancer tissues. Volunteers with healthy oral tissue will be included to further test the computer software. Secondary aims include collecting pilot safety data and feedback regarding the use of this device. If successful, the results from this pilot study will lead to a bigger trial to further study how the device can be used for cancer diagnosis.",[87,28,88,89,90],"Oral Cancer","Oral Lesions","Oral Pre-cancer","Mouth Cancer",[92,93,94,95,96,97,98,99,100,101],"oral cancer","mouth lesions","dysplastic oral lesions","mouth cancer","pre-cancer","mouth pre-cancer","oral pre-cancer","oral lesions","oral biopsy","polarized Raman spectroscopy","NOT_YET_RECRUITING","2025-08-13",{"date":105,"type":33},"2025-08-19",{"date":107,"type":21},"2025-09-01",{"date":109,"type":21},"2025-10-31",{"name":111,"class":74},"King's College London",1,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":112},"100549158","phase-1-study-of-vegf-a-targeting-nir-ii-fluorescence-endoscopy-in-the-gastrointestinal-tract-100549158","NCT06430372","Study of VEGF-A Targeting NIR-II Fluorescence Endoscopy in the Gastrointestinal Tract","Study of Vascular Endothelial Growth Factor A Targeting NIR-II Fluorescence in the Endoscopy of Gastrointestinal Tract","Inclusion Criteria:\n\n* Known or suspected gastrointestinal lesions.\n* Scheduled for a clinically-indicated endoscopy.\n* Mentally competent person, 18 years or older.\n* Approved to sign the informed consent.\n* Adequate potential for follow-up.\n\nExclusion Criteria:\n\n* Subjects with known allergy or negative reaction to ICG or derivatives.\n* Undesirable function of heart, lung, kidney, or any other organs.\n* Enrolled in other trials in the past 3 months.\n* Pregnant or trying to conceive.\n* Unable to tolerate an endoscopy.\n* Medical or psychiatric conditions that compromise the patient's ability to give informed consent.\n* The researchers considered inappropriate to be included.","75 Years",{"count":122,"type":21},30,[124],"PHASE1","In this study, the investigators are studying new ways to look for abnormal tissues of the gastrointestinal tract during an endoscopy. We are using a VEGF-A targeting fluorescent probe and a NIR-II fluorescent endoscope to help detect abnormal tissues that are hard to see by the naked eye.\n\nThe main purposes of this study include:\n\n1. To translate the NIR-II approach into the endoscopy, and understand its advantages and limitations on detecting abnormal tissues in gastrointestinal.\n2. To validate whether topical administration of a targeting probe can stick to abnormal tissues and be detected by the NIR-II endoscope.\n3. To validate the safety and effectiveness of the topical administration of VEGF-A targeting probes for clinical application.",[127,28,128],"Gastrointestinal Carcinoma","Gastrointestinal Polyp","2025-05-08",{"date":131,"type":33},"2025-05-13",{"date":133,"type":33},"2023-07-20",{"date":135,"type":21},"2026-05-30",{"name":137,"class":74},"Institute of Automation, Chinese Academy of Sciences"]